ClinicalTrials.gg
CompletedNCT06733428Updated Feb 4, 2025

Agreement and Precision Study

An observational study in Eye Abnormalities and Normal Eyes, sponsored by Topcon Corporation. Completed at 1 site in United States. Open to participants aged 22 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Topcon Corporation · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
108
Ages
22 Years and older
Sex
All
01

Study summary

To evaluate the performance of pachymetry function

02

Conditions studied

  • Eye Abnormalities
  • Normal Eyes

Browse trials for

03

In context

Eye Abnormalities

28 studies on the registry are indexed under Eye Abnormalities; 3 are open to participants now.

This study's enrollment of 108 is close to the median of 100 across 14 observational studies indexed under Eye Abnormalities.

Browse Eye Abnormalities studies →

Lead sponsor

Topcon Corporation is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Subjects seeing an eye doctor that have normal cornea, cornea abnormality, or glaucoma

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide voluntary written consent
  • Age at least 22 years old
  • For glaucoma group only, visual field defect and optic nerve damage consistent with glaucoma
  • For cornea group only, cornea abnormality

Exclusion criteria

Exclusion Criteria:

  • Ocular condition that may affect ability to perform cornea measurements
  • Have or is suspected to have ocular infection
  • Unable to tolerate eye testing
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
108 participants (actual)
Patient registry
No

Groups and cohorts

  • Normal

    Subjects with healthy cornea

    Device: Pachymeter

  • Cornea

    Subjects with abnormal cornea

    Device: Pachymeter

  • Glaucoma

    Subjects with glaucoma

    Device: Pachymeter

Interventions

  • DevicePachymeter

    Measure the thickness of the cornea

    Also known as: TRK-3 auto kerato-refracto tonometer

06

What researchers measure

Primary outcomes

  1. Cornea thickness

    thickness of the cornea

    Time frame: 1 day

07

Study locations

1 site
  • Illinois College of Optometry
    Chicago, Illinois 60616, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06733428
Lead sponsor
Topcon Corporation
Responsible party
Sponsor
First posted
Dec 13, 2024
Start date
Jan 9, 2025
Primary completion
Jan 28, 2025
Completion
Jan 28, 2025
Last update
Feb 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion